# To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus

> **NCT05926414** · — · ACTIVE_NOT_RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 15000 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Enavogliflozin
- **DRUG:** Enavogliflozin

## Key facts

- **NCT ID:** NCT05926414
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-21
- **Primary completion:** 2025-01-17
- **Final completion:** 2025-12-31
- **Target enrollment:** 15000 (ESTIMATED)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05926414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05926414, "To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05926414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*